Inaktiver Wert

Andere Sprachen NanoViricides Inc OTC Bulletin Board

Aktien

US6300871042

Schlusskurs OTC Bulletin Board Andere Börsenplätze
- ^USD	-

15.05.	NanoViricides, Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 31. März 2024	CI
14.05.	NanoViricides, Inc. kündigt ein neuartiges antivirales Breitspektrum-Medikament mit Aktivität gegen RSV an	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	15.05.
NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV	14.05.
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox	08.05.
NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Influenza A	06.05.
NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon	30.04.
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	14.02.
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	01.02.
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	29.01.
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	28.11.
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14.11.
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	14.11.
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	13.10.23
Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2	21.08.23
Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides	11.07.23
Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well	06.07.23
Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun	29.06.23
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15.05.23
NanoViricides Files $150 Million Mixed Shelf	08.05.23
NanoViricides, Inc. Enters into License Agreement with Karveer Meditech Private Limited	31.03.23
NANOVIRICIDES, INC. : EF Hutton toujours à l'achat	28.02.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NanoViricides Inc OTC Bulletin Board

Aktien

US6300871042

Andere Sprachen

Filter